DAWN
Price
$7.20
Change
-$0.27 (-3.61%)
Updated
Oct 17, 04:59 PM (EDT)
Capitalization
765.17M
24 days until earnings call
PMCB
Price
$0.96
Change
-$0.02 (-2.04%)
Updated
Oct 17, 04:59 PM (EDT)
Capitalization
6.63M
60 days until earnings call
Interact to see
Advertisement

DAWN vs PMCB

Header iconDAWN vs PMCB Comparison
Open Charts DAWN vs PMCBBanner chart's image
Day One Biopharmaceuticals
Price$7.20
Change-$0.27 (-3.61%)
Volume$15.5K
Capitalization765.17M
PharmaCyte Biotech
Price$0.96
Change-$0.02 (-2.04%)
Volume$364
Capitalization6.63M
DAWN vs PMCB Comparison Chart in %
DAWN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PMCB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DAWN vs. PMCB commentary
Oct 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DAWN is a Hold and PMCB is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 18, 2025
Stock price -- (DAWN: $7.47 vs. PMCB: $0.98)
Brand notoriety: DAWN and PMCB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DAWN: 115% vs. PMCB: 57%
Market capitalization -- DAWN: $737.51M vs. PMCB: $6.59M
DAWN [@Biotechnology] is valued at $737.51M. PMCB’s [@Biotechnology] market capitalization is $6.59M. The market cap for tickers in the [@Biotechnology] industry ranges from $106.87B to $0. The average market capitalization across the [@Biotechnology] industry is $2.06B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DAWN’s FA Score shows that 0 FA rating(s) are green whilePMCB’s FA Score has 1 green FA rating(s).

  • DAWN’s FA Score: 0 green, 5 red.
  • PMCB’s FA Score: 1 green, 4 red.
According to our system of comparison, PMCB is a better buy in the long-term than DAWN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DAWN’s TA Score shows that 6 TA indicator(s) are bullish while PMCB’s TA Score has 2 bullish TA indicator(s).

  • DAWN’s TA Score: 6 bullish, 4 bearish.
  • PMCB’s TA Score: 2 bullish, 4 bearish.
According to our system of comparison, DAWN is a better buy in the short-term than PMCB.

Price Growth

DAWN (@Biotechnology) experienced а +0.40% price change this week, while PMCB (@Biotechnology) price change was -3.47% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.56%. For the same industry, the average monthly price growth was +16.02%, and the average quarterly price growth was +79.42%.

Reported Earning Dates

DAWN is expected to report earnings on Nov 10, 2025.

PMCB is expected to report earnings on Dec 17, 2025.

Industries' Descriptions

@Biotechnology (+1.56% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DAWN($765M) has a higher market cap than PMCB($6.63M). PMCB YTD gains are higher at: -37.898 vs. DAWN (-41.042). PMCB has higher annual earnings (EBITDA): -3.96M vs. DAWN (-108.37M). DAWN has more cash in the bank: 453M vs. PMCB (13.4M). PMCB has less debt than DAWN: PMCB (75.2K) vs DAWN (3M). DAWN has higher revenues than PMCB: DAWN (188M) vs PMCB (0).
DAWNPMCBDAWN / PMCB
Capitalization765M6.63M11,545%
EBITDA-108.37M-3.96M2,739%
Gain YTD-41.042-37.898108%
P/E RatioN/A16.25-
Revenue188M0-
Total Cash453M13.4M3,381%
Total Debt3M75.2K3,993%
FUNDAMENTALS RATINGS
PMCB: Fundamental Ratings
PMCB
OUTLOOK RATING
1..100
75
VALUATION
overvalued / fair valued / undervalued
1..100
62
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
81
P/E GROWTH RATING
1..100
2
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
DAWNPMCB
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
75%
Momentum
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
83%
MACD
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
86%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 10 days ago
80%
Bullish Trend 15 days ago
75%
Declines
ODDS (%)
Bearish Trend 4 days ago
81%
Bearish Trend 2 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
89%
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
83%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
DAWN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PMCB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
USEMX26.170.13
+0.50%
Victory Emerging Markets
ISTNX95.17-0.04
-0.04%
Macquarie Science and Technology R6
SPFZX34.51-0.16
-0.46%
PGIM Jennison Focused Growth Z
GMCQX14.27-0.10
-0.70%
GMO US Equity VI
HEQCX5.75-0.06
-1.03%
Monteagle Opportunity Equity Instl

DAWN and

Correlation & Price change

A.I.dvisor indicates that over the last year, DAWN has been loosely correlated with RVMD. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if DAWN jumps, then RVMD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DAWN
1D Price
Change %
DAWN100%
-3.98%
RVMD - DAWN
49%
Loosely correlated
+0.24%
DNLI - DAWN
49%
Loosely correlated
+2.51%
OCUL - DAWN
48%
Loosely correlated
+2.22%
IDYA - DAWN
48%
Loosely correlated
-2.43%
IMTX - DAWN
46%
Loosely correlated
-5.82%
More

PMCB and

Correlation & Price change

A.I.dvisor tells us that PMCB and FATE have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PMCB and FATE's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PMCB
1D Price
Change %
PMCB100%
-3.46%
FATE - PMCB
33%
Poorly correlated
+0.65%
DAWN - PMCB
30%
Poorly correlated
-3.98%
MBRX - PMCB
28%
Poorly correlated
-5.41%
BTAI - PMCB
28%
Poorly correlated
-8.21%
DTIL - PMCB
28%
Poorly correlated
+2.15%
More